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Abstract 
Background: Little is known about prevalence of drug resistance among HIV-infected 
Ugandans, a setting with over 15 years of public-sector access to antiretroviral therapy (ART) 
and where virological monitoring was only recently introduced.   
Setting: This study was conducted in the adults' out-patient clinic of the Infectious Diseases 
Institute, Kampala, Uganda. 
Methods: HIV genotyping was performed in ART naïve patients and in treatment experienced 
patients on ART for ≥ six months with virological failure (≥1000 copies/mL).  
Results: A total of 152 ART naïve and 2511 ART experienced patients were included. 
Transmitted drug resistance was detected in 9 (5.9%) patients. After a median time on ART of 
4.7 years (interquartile range (IQR): 2.5-8.7), 190 patients (7.6%) had virological failure with 
a median viral load of 4.4 log10 copies/mL (IQR:3.9-4.9). Additionally, 146 patients had a 
viral load between 51 and 999 copies/ml. Most patients with virological failure (142, 74.7%) 
were on first-line ART. For 163 (85.8%) ART experienced patients genotype results were 
available. Relevant drug resistance mutations were observed in 135 (82.8%), of which 103 
(63.2%) had resistance to two drug classes, and 11 (6.7%) had resistance to all drug classes 
available in Uganda.  
Conclusion: The prevalence of transmitted drug resistance was lower than recently reported 
by the WHO. With 92% of all patients virologically suppressed on ART, the prevalence of 
virological failure was low when a cut-off of 1000 copies/mL is applied, and is in-line with 
the third of the 90-90-90 UNAIDS targets. However, most failing patients had developed 
multi-class drug resistance. 
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INTRODUCTION  1 
In Uganda, antiretroviral therapy (ART) was first made available for selected HIV-infected 2 
patients through the private sector and small pilot research studies in 1998, approximately 5 3 
years earlier than in other countries in sub-Saharan Africa.1 When low-cost, high-quality 4 
generic antiretroviral drugs became available in 2001, the Ugandan government introduced 5 
ART for HIV-infected patients with advanced HIV disease funded by the World Bank Multi-6 
Sectoral AIDS Project (MAP).2,3 Since 2003, ART in Uganda is largely funded by the U.S. 7 
President’s Emergency Plan for HIVAIDS Relief (PEPFAR) and has been made available to a 8 
large part of HIV-infected Ugandans based on existing national  guidelines.4 According to the 9 
Ugandan Population HIV Impact Assessment (UPHIA), 1.3 Million people in Uganda were 10 
living with HIV in 2016 (prevalence 6.2% among adults), and the ART coverage was 60%.5 11 
In-line with WHO guidelines, first-line treatment regimens in Uganda consist of a fixed-dose 12 
combination of two nucleoside-reverse-transcriptase-inhibitors (NRTI), either AZT/3TC or 13 
TDF/3TC, with one non-nucleoside-reverse-transcriptase-inhibitor (NNRTI), either 14 
nevirapine or efavirenz.4 Second-line treatment options are reserved for patients failing first-15 
line treatment and consist of a protease inhibitor (PI) with two NRTI. Integrase Inhibitors 16 
such as raltegravir or dolutegravir are considered third-line drugs and were only available 17 
through research studies or private purchase at the time of study implementation.  18 
Previous studies on the prevalence of transmitted drug resistance in Uganda mainly focused 19 
on key populations or had small patient numbers. For instance, a study from 2004 included 81 20 
patients from Kampala and found a prevalence of transmitted drug resistance of 7%.6 A more 21 
recent, but similarly small study examined transmitted drug resistance among Ugandan 22 
fishing communities, which is a high-risk group around Lake Victoria, and found resistance to 23 
NNRTI in three of 47 (6.4%) treatment naïve patients.7  24 
 25 
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As resistance mutations impact therapeutic outcomes, in developed countries genotypic 26 
resistance testing is recommended before starting treatment and before considering a switch 27 
of regimen.8 However, genotypic resistance testing remains costly and is therefore reserved 28 
for research or privately paid for in resource-limited countries including Uganda. A meta-29 
analysis has shown a higher prevalence of HIV drug resistance among ART naïve patients in 30 
East Africa compared to other regions with a 29% increase of HIV drug resistance per year 31 
since the ART roll out, compared to lower rates in Southern Africa (14%) and Central and 32 
West Africa (3%).9 Due to growing evidence of increasing resistance to ART, there is need 33 
for further documentation of the current state of both acquired and transmitted drug resistance 34 
in Uganda.10–12 The objective of our study was to report the type and frequency of HIV drug 35 
resistance among ART naïve, as well as ART-experienced urban Ugandan adults by 36 
performing a cross-sectional study in one of the largest HIV treatment centers in Kampala. 37 
 38 
METHODS 39 
Setting  40 
We conducted a cross-sectional study at the adult clinic of the Infectious Diseases Institute 41 
(IDI), College of Health Sciences, Makerere University in Kampala, Uganda, between June 4 42 
and September 30, 2015. The IDI is a center of excellence for HIV treatment located at the 43 
national referral hospital complex, and currently cares for over 8000 registered patients 44 
infected with HIV.13 Up to December 2014, patients on ART were monitored with CD4 count 45 
measurements every 6 months, while viral load testing was made available only for patients 46 
who were thought to have treatment failure based on immunological or clinical criteria.14  47 
All HIV-infected patients presenting at the IDI during the study period, who were 18 years or 48 
older, ART naïve or on ART for ≥ 6 months, and due for a CD4 cell count measurement were 49 
eligible for study participation. As defined by the WHO, transmitted HIV drug resistance is 50 
detected in ARV naive people with no history of antiretroviral drug exposure.15 Therefore, all 51 
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patients currently without ART but prior exposure to ART, such as women with a history of 52 
treatment for the prevention-of-mother-to-child-transmission (PMTCT), were excluded. 53 
Patients with a history of any blinded ART regimen in the context of clinical trials were 54 
excluded as well. Patients were consecutively screened and enrolled by trained study staff.  55 
Study procedures  56 
For each participant, we collected information on demographics, social and educational 57 
background, ART history, concomitant medication including herbal remedies, alcohol and 58 
recreational drug-use, information on adherence by self-report, side effects, past CD4 cell 59 
counts and, if applicable, past viral load results. Results for viral loads and genotypic 60 
resistance testing were collected prospectively. Venous blood was drawn from patients on 61 
ART for viral load measurement, and plasma storage at -80°C. CD4 cell counts (BD 62 
FACSCalibur Flow Cytometer: 4-Color) and viral load measurements (COBAS® AmpliPrep 63 
/ COBAS® TaqMan® HIV-1 Test, v2.0, Roche Diagnostics, cut-off 20 copies/ml) were 64 
performed at the Makerere-University-John-Hopkins-University (MUJHU) CORE laboratory 65 
certified by the College of American Pathologists. For ART naïve patients, blood was 66 
sampled for plasma storage only. Genotyping was requested at the MRC/UVRI Uganda 67 
Research Unit on AIDS, HIV Drug Resistance Reference Laboratory for all ART naïve 68 
patients and ART experienced patients with virological failure, defined as viral load ≥1000 69 
copies/mL. As previously described, viral RNA was extracted from 140ul of plasma using the 70 
QIAmp Viral RNA mini kit (Qiagen), the entire protease (codons 1–99) and amino terminus 71 
of reverse transcriptase (codons 1–320) were amplified and sequenced using the ABI 3500 72 
machine (Applied Biosystems).12 Sequences were base-called using Sequencher v5.2.4 and 73 
drug resistance mutations (DRMs) were analysed using the Stanford HIVdb Program 74 
(https://hivdb.stanford.edu/hivdb/by-mutations). The assigned DRMs were interpreted using 75 
the 2009 WHO list for epidemiological surveys. HIV-1 subtyping was done using SCUEAL 76 
(http://www.datamonkey.org/dataupload_scueal.php) and REGA (www.bioafrica.net/rega-77 
AC
CE
PT
E
Copyright © 2018   The Author(s). Published by Wolters Kluwer Health, Inc. 
 6
genotype/html/subtypinghiv.html) online software. Basic phylogenies were performed to 78 
determine sequence relatedness and to rule out contaminations. Viral sequences are available 79 
in Genbank accession numbers MF565526 – MF565688.  80 
Data management and statistical analysis  81 
Data was collected from patient interview, extracted from the electronic medical record 82 
(Integrated Clinic Enterprise Application, ICEA)16 or paper file and entered into DataFax 83 
forms specially designed for this study. The data management system DataFax is designated 84 
to manage paper data forms. The forms are faxed to the DataFax server where they are read 85 
using intelligent characters-recognition and populate the study database.   86 
Univariate and multivariate logistic regressions were done to identify risk factors for 87 
virological failure in patients on first- and second-line ART. The following potential risk 88 
factors or correlates for virological failure were considered in the univariate analysis: age, 89 
gender, current ART regimen, years on ART, CD4 cell count, number of children, marital 90 
status, adherence to ART, reported side effects, and previous viral load measurements. For the 91 
subsequent multivariate analysis we selected all variables with a p-value < 0.1 in the 92 
univariate model, checked for multicollinearity, and in case of multicollinearity selected 93 
according to clinical relevance.  94 
Ethical considerations 95 
This study was reviewed and approved by the Makerere University School of Biomedical 96 
Research and Ethics Committee (SBS254), and the Uganda National Council for Science and 97 
Technology (HS 1800). The study was registered on ClinicalTrials.gov (NCT02507921). 98 
Written informed consent was obtained from all participants prior to enrollment. The funders 99 
had no role in study design, data collection, data analysis, data interpretation, or writing of the 100 
manuscript.   101 
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RESULTS 102 
A total of 2808 participants were enrolled in the study consisting of 220 ART naïve and 2588 103 
ART experienced respectively. Figure 1 depicts the disposition of patients from screening to 104 
enrollment.  105 
ART naïve patients 106 
After withdrawing 14 patients with a history of PMTCT, 206 ART naïve patients were 107 
included. The median age was 33 years (IQR: 26-41), and the majority of patients had WHO 108 
disease stage 1 (84, 40.8%) or 2 (76, 36.9%). The median CD4 cell count was 511cells/uL 109 
(IQR: 284-713). A total of 91 (44.2%) were either married or cohabitating, of which 59 110 
(64.8%) reported to have an HIV-infected partner. The majority of the partners (54, 91.5%) 111 
were already on ART. Fourteen patients (6.8%) reported to have HIV-infected children. 112 
Drug resistance testing could be performed in 152 ART naïve patients. Mutations associated 113 
with HIV drug resistance were found in 9/152 (5.9%) patients. Five patients (5/152, 3.3%) 114 
had any NRTI mutation (K65R: 1, M184V: 2, other: 2), and 8/152 (5.3%) had any NNRTI 115 
mutation (K101E: 3, Y181C: 2, K103N: 2, other: 4). No major PI mutation was detected. 116 
ART experienced patients 117 
After withdrawing 77 patients, 2511 ART experienced patients were included in this study, of 118 
which 1577 (62.8%) were female. Patients were withdrawn for the following reasons: history 119 
of blinded ART regimen (n=59), current ART regimen <6 months (n=12), and unwillingness 120 
to give a blood sample (n=6). Overall, study participants had been on ART for a median time 121 
of 4.7 years (IQR: 2.5-8.7 years). A total of 190 (7.6%) participants had virological failure 122 
with a median viral load of 4.4 log10 copies/mL (IQR: 3.9-4.9 log10 copies/mL). The majority 123 
of patients with virological failure were female (131/190, 69.0%) and on first-line ART 124 
(142/190, 74.7%). Table 1 shows baseline characteristics of study participants with 125 
virological suppression, as well as virological failure disaggregated by subjects failing first- 126 
and second-line ART regimens.  127 
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Risk factors for virological failure in patients failing first- and second-line ART were 128 
evaluated by univariate and multivariate analyses. As shown in Figure 2 for all patients, 129 
virological failure was significantly more likely in patients on second-line ART (adjusted 130 
odds ratio (aOR): 2.95, 95% confidence interval (95%CI): 1.87-4.65). Furthermore, being 131 
separated from the spouse (aOR: 1.86, 95%CI: 1.12-3.01) and reported side effects (aOR: 132 
1.94, 95%CI: 1.18-3.19) were associated with virological failure. Previous viral load 133 
measurements (aOR: 0.55, 95%CI: 0.37-0.83), as well as excellent adherence (aOR: 0.41, 134 
95%CI: 0.24-0.71) were protective of virological failure. Results of the univariate and 135 
multivariate analysis were further disaggregated by patients failing on first- and second-line 136 
ART. For patients on first-line ART (Table 2A), reported side-effects (aOR: 2.01, 95%CI: 137 
1.17-3.46), as well as living separated from the spouse (aOR: 2.21, 95%CI: 1.29-3.81) were 138 
strongly associated with virological failure. Excellent adherence was protective of virological 139 
failure (aOR: 0.33, 95%CI: 0.18-0.61). In our study population, virological failure was 140 
significantly more likely to occur in patients on second-line treatment. In these patients (Table 141 
2B), virological failure was associated with being single or separated from the spouse (aOR: 142 
1.46, 95%CI: 0.55-3.92). A low CD4 cell count was not associated with virological failure. 143 
However, this may be due to a small sample size of patients failing on second-line treatment 144 
(N=48). Previous viral load measurements (aOR: 0.21, 95%CI: 0.09-0.52) were strongly 145 
protective of virological failure in patients on second-line ART. 146 
Of 190 patients with a viral load >1000 copies/mL, HIV genotyping tests were available from 147 
163 (85.8%) cases. HIV subtypes A (47.2%) and D (34.4%) were most common, 16.0% were 148 
recombinants. Subtypes C (1.8%) and G (0.6%) were rarely seen. Relevant drug resistance 149 
mutations were observed in 135 (82.8%), of which 103 (63.2%) had resistance to two drug 150 
classes, and 11 (6.7%) had resistance to all three drug classes available in Uganda. PI 151 
mutations were observed in 13 (8.0%) patients. Any NRTI mutation was found in 122 152 
(74.8%) patients, most commonly M184V (65.0%). A total of 125 (76.7%) patients had any 153 
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NNRTI mutation, most commonly K103N (42.9%). Of the 163 patients with available 154 
resistance testing, 28 (17.2%) had a K65R mutation. Almost all of these patients were 155 
currently on treatment with tenofovir (22/28, 78.6%). Figures 3 A&B show the resistance 156 
mutations found in patients failing first- and second-line ART with available sequence data. 157 
In this study, resistance testing was done only in patients with a viral load >1000 copies/mL. 158 
A viral load between 51 and 500 copies/mL was detected in 127 (5.1%) participants (median 159 
viral load 130 copies/mL, IQR: 82-201 copies/mL), while 19 (0.8%) study participants had a 160 
viral load between 501 and 999 copies/ml (median viral load 623 copies/mL, IQR: 565-797 161 
copies/mL). Thus, if a cut-off of 50 copies/mL is applied, as is the case in resource-rich 162 
settings, the rate of virological failure almost doubles to 345 patients (13.4%). 163 
 164 
DISCUSSION 165 
Our study indicates a low level of transmitted HIV drug resistance in this large urban HIV 166 
treatment center in a setting with public-sector ART access for more than one and a half 167 
decades. Given the paucity of published HIV drug resistance studies in ART naïve individuals 168 
in the region, our findings provide some insight on the level of transmitted drug resistance for 169 
similar settings in the region. Additionally, our study found a high rate of virological 170 
suppression. With over 92% of all patients virologically suppressed on ART, the overall 171 
prevalence of virological failure was low in our study population, and this is in-line with the 172 
third of the 90-90-90 UNAIDS targets.17 However, most failing patients had developed multi-173 
class drug resistance.  174 
Transmitted drug resistance 175 
While there is limited data available on acquired resistance in Uganda, there is even less on 176 
transmitted drug resistance among HIV-infected Ugandans.12 We found a proportion of 5.9% 177 
among our study population, which according to the WHO grading system is the cut-off 178 
between low (<5%) and moderate (5-15%).  Despite over 10 years of widespread ART 179 
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availability in Uganda, according to this finding the prevalence of transmitted drug resistance 180 
in adults seeking care in our clinic seems to be low. Furthermore, mutations to PI, which are 181 
commonly used as second-line treatment options, were not observed. These findings are in 182 
line with previous studies from Uganda, which showed low rates of transmitted drug 183 
resistance in rural areas, as well as in urban settings ten years after the introduction of 184 
ART.6,18 185 
The most recent report on HIV drug resistance published by the WHO found a high 186 
proportion of patients with pretreatment drug resistance in Uganda.15 According to the WHO 187 
definition, pretreatment drug resistance is detected in treatment naive people initiating ART 188 
or people with prior antiretroviral drug exposure initiating or reinitiating first-line ART. Thus, 189 
pretreatment drug resistance includes transmitted drug resistance but can be acquired as well. 190 
The data on pretreatment drug resistance from Uganda included 342 adults (203 women, 191 
65.4%), of which 296 (78.7%) had no prior exposure to ART. According to the report, levels 192 
of NNRTI pretreatment drug resistance were greater than 10% in three out of four countries in 193 
the African region, ranging from 8.1% (95% CI 4.3–14.7) in Cameroon to 15.4% (95% CI 194 
10.3–22.5) in Uganda. Any transmitted drug resistance mutation was found in 18.1% (95% CI 195 
12.7–25.2) of Ugandan patients. Compared to the WHO report our findings on transmitted 196 
drug resistance are much lower. Generally, surveillance data can be heterogeneous. The WHO 197 
report used a nationally representative sampling method described in detail in the report as 198 
opposed to site specific data. Secondly, considerable fluctuations over time have been 199 
observed in other countries, which can so far only partly be explained. One reason for these 200 
fluctuations was the introduction of new drugs as seen for boosted PIs in Switzerland.19 We 201 
conclude that more data is needed in order to complete the picture. 202 
Virological failure 203 
Our study found a high rate of virological suppression. Using a cut-off for virological failure 204 
of 1000 copies/mL, over 92% of all patients were suppressed on ART, which is in-line with 205 
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the third of the 90-90-90 UNAIDS targets.17 This is especially encouraging because for 206 
several years these patients were monitored using CD4 cell measurements only. Optimal 207 
adherence, high-quality clinical management, and consistent drug supplies probably 208 
contributed to these outcomes. The high proportion of patients virologically suppressed on 209 
first-line treatment is in line with findings from other studies previously conducted at the 210 
IDI.20 In order to maintain a high rate of virological suppression the clinic adopted several 211 
differentiated care models, such as the nurse-visit or pharmacy-refill program.21 In both 212 
models, task shifting enables clinicians to concentrate on challenging cases. As the IDI is a 213 
center of excellence for HIV care, our study findings cannot be generalized. This aspect 214 
becomes even more apparent if our results are compared to the data provided by the UPHIA, 215 
which reports a prevalence of virological suppression among all HIV-positive Ugandan adults 216 
aged 15 to 64 of only 59.6% (62.9% among females and 53.6% among males).5 However, the 217 
results of our study demonstrate how well patients can do within an optimal setting.  218 
Nevertheless, it is notable that the proportion of patients with virological failure doubles if a 219 
cut-off of 50 copies/mL is applied, as is standard in many resource-rich settings. In our study, 220 
146 patients had a viral load between 51 and 999 copies/mL. Using a cut-off of 1000 221 
copies/mL for treatment failure makes sense in the context of “treatment as prevention”, as it 222 
is well described that transmission practically does not take place below this cut-off. 223 
However, the development of HIV drug resistance among patients with low-level viremia 224 
may be underestimated. In fact, a recent nation-wide study from France found that 48.5% of 225 
samples from patients with a viral load between 51 and 200 copies/mL harbored resistance 226 
mutations.22 Furthermore, recently published data from a South African cohort study which 227 
included over 70 000 HIV-positive patients from 57 clinical sites identified low-level 228 
viraemia (defined as a viral load of 51-999 copies/mL) in 23% of patients on first-line 229 
treatment. According to the authors, low-level viraemia was associated with increased hazards 230 
of virological failure (hazard ratio [HR] 2·6, 95% CI 2·5–2·8; p<0·0001) and switch to 231 
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second-line ART (HR 5·2, 4·4–6·1; p<0·0001]) compared with virological suppression of 232 
less than 50 copies/mL.23 These findings challenge the definition of therapeutic failure in 233 
guidelines using a cut-off of 1000 copies/mL, and evidence suggests that strategies for the 234 
management of low-level viraemia need to be incorporated into international guidelines in 235 
order to meet UNAIDS-defined targets.  236 
Acquired drug resistance 237 
The high proportion of virological suppression on ART is encouraging. However, most study 238 
participants with virological failure had developed resistance to more than one drug class, 239 
suggesting that failing regimens not identified by CD4 cell count monitoring in a timely 240 
fashion had been in place for a prolonged period. This study finding is most worrisome as 241 
efficacious treatment options are limited for patients with multi-class drug resistance in this 242 
setting, which puts these patients at high risk of disease progression and transmission of 243 
resistant virus strains. The accumulation of drug resistance mutations over time in patients 244 
with continued virological failure was shown in previously conducted studies from Uganda 245 
and other sub-Saharan African countries.24,25  A systematic review and meta-analysis which 246 
included 8376 patients from 8 cohorts and two prospective studies showed a significantly 247 
higher proportion of resistance mutations at virological failure in patients monitored less 248 
frequently.26 This is in-line with our observation that previous viral load measurements were 249 
protective of virological failure and thus the development of resistance mutations in patients 250 
on second-line ART.  251 
The distribution of mutations found in our study is largely in line with findings from other 252 
studies conducted in the region. A systematic review of 89 studies with 13288 patients from 253 
sub-Saharan Africa found the prevalence of viral suppression at 12 months to be 76%.27 In 254 
patients with virological failure the most common resistance mutations reported by the 255 
authors were M184V (65%) and K103N (52%) while thymidine-analogue mutations (TAMs) 256 
and K65R were much less common (5 - 20%). The PharmAccess African Studies to Evaluate 257 
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Resistance (PASER), which evaluated data from six African countries, found that 8.5% of 258 
patients with virological failure after 11-15 months of ART have more than one TAM.28  259 
Among the 163 patients with available resistance data in our study, 54 (33.1%) were on TDF-260 
containing regimens. Of these, 22 (40.7%) had a K65R mutation compared to only 28 261 
(17.8%) among the entire study population. A recent study on the global epidemiology of 262 
HIV drug resistance after failure of WHO recommended first-line regimens was recently 263 
published.29 In low- and middle-income countries, the authors found drug resistance in a high 264 
proportion of patients failing treatment with tenofovir-containing regimens. Tenofovir 265 
resistance was highest in sub-Saharan Africa (370/654, 57%). The study findings reported 266 
here, as well as observations from other studies on emergence of resistance in the region 267 
stress the need for enhanced surveillance and preventive measures.30,31  268 
Our study has a few limitations. For one, women currently without ART but with a history of 269 
PMTCT (WHO option B) were excluded from participation. These women were excluded 270 
because they did not fulfill the criteria of being ART naïve or on a stable regimen for at least 271 
6 months. However, HIV drug resistance today plays an important role in these women, and 272 
further research focused specifically on this group is needed. A further limitation is that we 273 
failed to collect information on pregnancy, as well as on tuberculosis co-infection. Both 274 
aspects are relevant in the context of treatment failure and should have been taken into 275 
account. Furthermore, a number of resistance tests failed. We were unable to ascertain the 276 
cause of failure to genotype 54 samples of ART naïve and 36 samples of ART experienced 277 
participants. While this did not result in a selection bias, it reduced the number of available 278 
tests for this study analysis. However, the number of failed test seems to be in-line with other 279 
studies.22  280 
We conclude that the UNAIDS goal of 90% virological suppression on ART is achievable 281 
within an optimal treatment setting. However, if treatment failure occurred, a high proportion 282 
had developed multi-class drug resistance, which massively complicates sufficient treatment 283 
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in this setting. Furthermore, if a cut-off for treatment failure of 50 copies/mL is applied the 284 
rate of patients with virological failure doubles and most likely resistance among these 285 
patients is underestimated. As ART scale-up continues in the region, close surveillance of 286 
HIV drug resistance - both acquired and transmitted - is essential to assess optimal treatment 287 
regimens available to patients, and thereby prevent the further emergence and spread of 288 
resistant strains.  289 
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Table 1: Baseline characteristics of patients with and without virological failure 
 
Characteristics Not failing 
N=2240 
Failing first-line 
N=142 
Failing second-line 
N=48 
Female gender (N, %) 1395 (62.3) 102 (71.8) 29 (60.4) 
Median age in years (IQR) 42 (35-49) 35 (28-42) 41 (35.8-45.5) 
WHO disease stage (N, %) 
1, 2 
3,4 
 
806 (36.0) 
1434 (64.0) 
 
60 (42.3) 
82 (57.7) 
 
11 (23.0) 
37 (77.0) 
Median CD4 cell count in cells/ul 
(IQR) 
Current 
Nadir 
 
491 (350-657) 
129 (44-235) 
 
254 (106.2-404.2) 
126.5 (43-202.8) 
 
325 (200-453) 
43.5 (9-106.5) 
Median time on ART in years 
(IQR) 
5.2 (2.8-9.4) 3.3 (1.8-5.1) 6.1 (4.3-9.9) 
Current ART regimen (N, %) 
First-line NNRTI-based 
TDF + XTC + NVP 
TDF + XTC + EFV 
ZDV + XTC + NVP 
ZDV + XTC + EFV 
ZDV + 3TC + TDF 
D4T + XTC + NVP 
ABC + XTC + EFV 
ABC + XTC + NVP 
Second-line PI-based 
ATV/r  
LPV/r 
 
1932 (86.3) 
138 
712 
624 
436 
7 
3 
7 
5 
308 (13.7) 
86 
222 
 
142 (100) 
16 (11.3) 
54 (38.0) 
47 (33.1) 
24 (16.9) 
1 (0.7) 
0 
0 
0 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
48 (100) 
16 (33.3) 
32 (66.6) 
 
Table legend: IQR= interquartile range; ART=antiretroviral therapy; NVP = nevirapine, EFV = efavirenz; TDF = 
tenofovir, ZDV = zidovudine, XTC = FTC or 3TC, ATV/r = ritonavir-boosted atazanavir, LPV/r = ritonavir-boosted 
lopinavir 
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Table 2: univariate and multivariate analyses of risk factors for virological failure in A) patients on first-line ART 
and B) patients on second-line ART 
 
A. Patients on first-line ART 
 Univariate analysis Multivariate analysis 
Variable OR 95% CI p-value OR 95% CI p-value 
age 0.12 (0.06,0.24) <0.001 0.07 (0.02,0.22) <0.001 
Male gender 0.74 (0.54,1.03) 0.08 0.44 (0.27,0.71) <0.001 
CD4 cell count in cells/ul 
<200 (reference) 
200-350 
351-500 
501-650 
>650 
 
 
0.07 
0.12 
0.23 
0.04 
 
 
(0.04,0.12) 
(0.07,0.17) 
(0.15,0.35) 
(0.02,0.08) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
0.04 
0.08 
0.19 
0.02 
 
 
(0.02,0.09) 
(0.04,0.14) 
(0.11,0.32) 
(0.01,0.06) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
Previous viral load 0.62 (0.44,0.86) 0.005 0.64 (0.41,0.99) 0.05 
Missed pills 
> 1/month (reference) 
Never 
1/month 
 
 
0.31 
0.66 
 
 
(0.2,0.48) 
(0.39,1.1) 
 
 
<0.001 
0.11 
 
 
0.33 
0.79 
 
 
(0.18,0.61) 
(0.4,1.55) 
 
 
<0.001 
0.49 
Side-effects 2.16 (1.43,3.25) <0.001 2.01 (1.17,3.46) 0.01 
Marital status 
Married (reference) 
single 
separated 
widowed 
cohabitating 
 
 
2.19 
1.95 
1.01 
1.35 
 
 
(1.45,3.31) 
(1.29,2.96) 
(0.61,1.68) 
(0.72,2.51) 
 
 
<0.001 
0.002 
0.98 
0.35 
 
 
0.98 
2.21 
1.36 
1.43 
 
 
(0.54,1.78) 
(1.29,3.81) 
(0.68,2.76) 
(0.65,3.14) 
 
 
0.95 
0.004 
0.39 
0.38 
Number of children 
0-3 (reference) 
>3 
 
 
0.70 
 
 
(0.5,0.96) 
 
 
0.03 
 
 
1.45 
 
 
(0.89,2.35) 
 
 
0.14 
 
 
B. Patients on second-line ART 
 Univariate analysis Multivariate analysis 
Variable OR 95% CI p-value OR 95% CI p-value 
age 0.12 0.06;2,97 0.39 0.43 0.06;2.97 0.39 
Male gender 0.74 0.54;1.03 0.08 0.81 0.35;1.87 0.62 
CD4 cell count in cells/ul 
<200 (reference) 
200-350 
351-500 
501-650 
>650 
 
 
0.07 
0.11 
0.23 
0.04 
 
 (0.04,0.12) 
(0.07,0.17) 
(0.15,0.35) 
(0.02,0.08) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
0.27 
0.60 
0.70 
0.10 
 
 
(0.07,1.03) 
(0.19,1.86) 
(0.23,2.13) 
(0.03,0.41) 
 
 
0.06 
0.37 
0.53 
0.001 
Previous viral load 0.62 (0.44,0.86) 0.01 0.21 (0.09,0.52)  <0.001 
Missed pills 
> 1/month (reference) 
Never 
1/month 
 
 
0.31 
0.66 
 
 
(0.2,0.48) 
(0.39,1.1) 
 
 
<0.001 
0.11 
 
 
1.11 
1.28 
 
 
(0.34,3.58) 
(0.31,5.23) 
 
 
0.87 
0.73 
Side-effects 2.18 (1.43,3.25) <0.001 1.34 (0.39,4.55) 0.64 
Marital status 
Married (reference) 
Single 
Separated 
Widowed 
cohabitating 
 
 
2.19 
1.95 
1.01 
1.35 
 
 
(1.45,3.31) 
(1.29,2.96) 
(0.61,1.68) 
(0.72,2.51) 
 
 
<0.001 
0.001 
0.98 
0.35 
 
 
1.46 
0.81 
0.64 
0.80 
 
 
(0.55,3.92) 
(0.27,2.47) 
(0.19,2.17) 
(0.15,4.14) 
 
 
0.45 
0.71 
0.47 
0.80 
Number of children 
0-3 (reference) 
>3 
 
 
0.70 
 
 
(0.5,0.96) 
 
 
0.03 
 
 
1.36 
 
 
(0.59,3.11) 
 
 
0.47 
 
Table legend: ART = antiretroviral treatment, OR = odds ratio, CI = confidence interval 
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Figure 1: enrollment process 
Figure legend: ART = antiretroviral treatment 
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Figure 2: Univariate and multivariate analysis of risk factors for virological failure 
Figure legend: cART = combination antiretroviral therapy 
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Figure 3A: Type and frequency of most prevalent resistance-associated mutations observed among 
patients failing first-line antiretroviral treatment (N= 121)  
 
Figure 3B: Type and frequency of most prevalent resistance-associated mutations observed among 
patients failing second-line antiretroviral treatment (N=36) 
 
Figure legend: NRTI = Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNRTI = Non- 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; PI = Protease Inhibitors 
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